These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9337680)

  • 1. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy.
    Berger T; Malayeri R; Doppelbauer A; Krajnik G; Huber H; Auff E; Pirker R
    Eur J Cancer; 1997 Aug; 33(9):1393-9. PubMed ID: 9337680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer.
    Postma TJ; Hoekman K; van Riel JM; Heimans JJ; Vermorken JB
    J Neurooncol; 1999; 45(3):241-6. PubMed ID: 10845395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy.
    Argyriou AA; Polychronopoulos P; Koutras A; Xiros N; Petsas T; Argyriou K; Kalofonos HP; Chroni E
    Eur J Cancer Care (Engl); 2007 May; 16(3):231-7. PubMed ID: 17508942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.
    Chaudhry V; Rowinsky EK; Sartorius SE; Donehower RC; Cornblath DR
    Ann Neurol; 1994 Mar; 35(3):304-11. PubMed ID: 7907208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
    Gordon AN; Stringer CA; Matthews CM; Willis DL; Nemunaitis J
    J Clin Oncol; 1997 May; 15(5):1965-73. PubMed ID: 9164208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin neuropathy: a prospective clinical and electrophysiological study in Chinese patients with ovarian carcinoma.
    Fu KK; Kai EF; Leung CK
    J Clin Pharm Ther; 1995 Jun; 20(3):167-72. PubMed ID: 7593379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer.
    Watanabe H; Yamamoto N; Tamura T; Shimoyama T; Hotta K; Inoue A; Sawada M; Akiyama Y; Kusaba H; Nokihara H; Sekine I; Kunitoh H; Ohe Y; Kodama T; Saijo N
    Jpn J Clin Oncol; 2003 Dec; 33(12):626-30. PubMed ID: 14769840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin.
    Cavaletti G; Bogliun G; Marzorati L; Zincone A; Marzola M; Colombo N; Tredici G
    Cancer; 1995 Mar; 75(5):1141-50. PubMed ID: 7850713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral neurotoxicity following high-dose cisplatin with glutathione: clinical and neurophysiological assessment.
    Pirovano C; Balzarini A; Böhm S; Oriana S; Spatti GB; Zunino F
    Tumori; 1992 Aug; 78(4):253-7. PubMed ID: 1334604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC).
    Bacon M; James K; Zee B
    Int J Gynecol Cancer; 2003; 13(4):428-34. PubMed ID: 12911718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer.
    Verstappen CC; Postma TJ; Hoekman K; Heimans JJ
    J Neurooncol; 2003 Jun; 63(2):201-5. PubMed ID: 12825825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.
    Mayerhofer K; Bodner-Adler B; Bodner K; Leodolter S; Kainz C
    Anticancer Res; 2000; 20(5C):4047-50. PubMed ID: 11268499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?
    Argyriou AA; Polychronopoulos P; Koutras A; Iconomou G; Iconomou A; Kalofonos HP; Chroni E
    Support Care Cancer; 2005 Aug; 13(8):647-51. PubMed ID: 15711945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies.
    Krarup-Hansen A; Helweg-Larsen S; Schmalbruch H; Rørth M; Krarup C
    Brain; 2007 Apr; 130(Pt 4):1076-88. PubMed ID: 17301082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel.
    Rose PG; Smrekar M
    Gynecol Oncol; 2003 Nov; 91(2):423-5. PubMed ID: 14599877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxic neuropathy in patients with pre-existing neuropathy.
    Chaudhry V; Chaudhry M; Crawford TO; Simmons-O'Brien E; Griffin JW
    Neurology; 2003 Jan; 60(2):337-40. PubMed ID: 12552058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-hour paclitaxel in the treatment of non-small cell lung cancer.
    Hainsworth JD; Greco FA
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):98-101. PubMed ID: 9007133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results.
    Argyriou AA; Chroni E; Koutras A; Iconomou G; Papapetropoulos S; Polychronopoulos P; Kalofonos HP
    Support Care Cancer; 2006 Nov; 14(11):1134-40. PubMed ID: 16622646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.